Table 8 The specific therapeutical program of all patients before and after R0 resection
Patients | Conversion therapies | Adjuvant therapies | |
|---|---|---|---|
Modalities | Intervals (days after the surgery) | ||
1 | HAIC + Lenvatinib + Camrelizumab | No | - |
2 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 29 |
3 | HAIC + Lenvatinib + Camrelizumab | No | - |
4 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Tislelizumab | 40 |
5 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 33 |
6 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 42 |
7 | TACE + Lenvatinib + Camrelizumab | TACE+Lenvatinib + Tislelizumab | 41 |
8 | HAIC + Lenvatinib + Camrelizumab | Tislelizumab | 43 |
9 | HAIC + Lenvatinib + Camrelizumab | No | - |
10W&W | HAIC + Apatinib + Camrelizumab | No | - |
11W&W | HAIC + Apatinib + Camrelizumab | Camrelizumab | - |
12 | HAIC + Lenvatinib + Camrelizumab | TACE + Lenvatinib + Camrelizumab | 33 |
13 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 30 |
14 | HAIC + Apatinib + Camrelizumab | TACE + Lenvatinib + Camrelizumab | 41 |
15 | TACE + Radiotherapy+ Lenvatinib | TACE + Lenvatinib | 50 |
16 | TACE + Lenvatinib + Camrelizumab | No | - |
17 | HAIC + Lenvatinib + Camrelizumab | Lenvatinib + Camrelizumab | 35 |
18 | TACE + Apatinib + Camrelizumab | Apatinib + Camrelizumab | 37 |
19 | TACE + Sorafenib + Camrelizumab | Camrelizumab | 39 |
20 | TACE + Apatinib + Camrelizumab | Apatinib + Camrelizumab | 43 |
21 | TACE + Lenvatinib | Lenvatinib | 35 |
22 | TACE + Lenvatinib | Lenvatinib | 60 |
23 | TACE + Sorafenib +Sintilimab | TACE + Sorafenib + Sintilimab | 33 |
24W&W | TACE + Sorafenib + Camrelizumab | Sorafenib + Camrelizumab | - |
25 | Sorafenib+ Sintilimab | Sintilimab | 28 |
26 | TACE + Lenvatinib | Lenvatinib | 12 |